Mycenax Biotech (4726) — Cash Flow Quality Index
Latest as of March 2022:
3.23x
Mycenax Biotech (4726) has a Cash Flow Quality Index of 3.23x as of March 2022. Operating cash flow of NT$59.07 Million exceeds net income of NT$18.31 Million, indicating high earnings quality where cash backs reported profits. Explore Mycenax Biotech cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
3.23x
Operating CF / Net Income
Operating Cash Flow
NT$59.07 Million
TWD
Net Income
NT$18.31 Million
TWD
Data as of
Mar 2022
Most recent filing
Mycenax Biotech Cash Flow Quality Index (2020–2020)
Historical Cash Flow Quality Index for Mycenax Biotech across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 4726 cash generation efficiency.
Annual Cash Flow Quality Index for Mycenax Biotech (2020–2020)
Year-by-year earnings quality comparison for Mycenax Biotech.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 5.63x | NT$174.17 Million | NT$30.95 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.